In this issue of Blood, Stepensky et al identify mutations of VPS45 as a new cause of congenital neutropenia and primary myelofibrosis. 1 
S
evere congenital neutropenia (SCN) is characterized by severe isolated neutropenia from birth, recurring bacterial infections, and a marked propensity to develop a myelodysplastic syndrome or acute myeloid leukemia. SCN is a genetically heterogeneous disorder (see figure) .
Mutations of ELANE encoding neutrophil elastase (NE) account for ;60% of cases (all in autosomal dominant or sporadic SCN). Mutations of HAX1, G6PC3, GFI1, G6PT1, WAS, and CSF3R collectively account for approximately 10% to 20% of cases of SCN. Thus, the genetic basis for approximately 20% to 30% of cases of SCN is unknown. Of note, all the aforementioned gene mutations are thought to induce neutropenia through the disruption of granulopoiesis. In contrast, mutations of CXCR4 or CXCR2 result in neutropenia through impaired release of neutrophils from the bone marrow to blood.
Stepensky While the mechanisms by which VPS45 deficiency leads to neutropenia and myelofibrosis are unclear, it is worth noting that loss-of-function mutations of genes implicated in protein trafficking to endosomes also are associated with congenital neutropenia, including LYST (Chédiak-Higashi syndrome); RAB27A (Griscelli syndrome); AP3B1 (Hermansky-Pudlak syndrome type 2); VPS13B (Cohen syndrome), and LAMTOR2 (see figure) . Each of these disorders is characterized by neutropenia and variable degrees of platelet dysfunction, albinism, and cytotoxic T-cell dysfunction. The selective defects in immune cells, such as neutrophils and cytotoxic T cells, platelets, and melanocytes, are likely due, at least in part, to the extensive network of secretory lysosomes in these cells. Of note, lysosomes and a granules were reduced in fibroblasts and platelets, respectively, from patients homozygous for Thr224Asn VPS45.
This study raises several important questions. First, what is the frequency of VPS45 mutations in unselected patients with SCN? Although the Thr224Asn VPS45 mutation is associated with distinct clinical features (ie, myelofibrosis), it is possible that other VPS45 mutations may present with neutropenia alone. Second, what are the molecular mechanisms by which Thr224Asn VPS45 induces neutropenia and myelofibrosis? Similar to SCN associated with ELANE, HAX1, or G6PC3 mutations, Stepensky et al show that neutrophils from patients with Thr224Asn VPS45 display increased apoptosis. Although the evidence that Thr224Asn VPS45 disrupts protein sorting to lysosomes is convincing, it is not clear how this results in increased apoptosis. Of note, previous studies have demonstrated that loss-of-function mutations of AP3B1, which also disrupt protein sorting to lysosomes, result in impaired targeting of NE to primary granules and accumulation of NE precursor in the endoplasmic reticulum. 3, 4 Accumulation of misfolded mutant NE in the endoplasmic reticulum with subsequent induction of the unfolded protein response has been implicated in the pathogenesis of SCN associated with ELANE mutations.
5,6
Thus, it is possible that impaired trafficking of NE (and other primary granule constituents) to granules in Thr224Asn VPS45 granulocytic precursors may disrupt granulopoiesis through the induction of the unfolded protein response.
VPS45 mutations can now be added to the growing list of gene mutations causing congenital neutropenia and should be considered in the differential diagnosis, especially for those children presenting with myelofibrosis. Studies to further define the molecular pathogenesis of this disorder will likely provide novel insights into the regulation of hematopoiesis and bone marrow fibrosis.
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